Compare Johnson & Johnson (JNJ) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Nuwellis Inc — how do they compare? Johnson & Johnson trades at $261.04 (market cap $626.09B), while Nuwellis Inc trades at $1.4 (market cap $542.80K). The key difference: Johnson & Johnson is far larger — about 1153445.1× Nuwellis Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| JNJ | NUWE | |
|---|---|---|
Market Cap | $626.09B | $542.80K |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $220.50 |
52-Week Low | $172.78 | $1.42 |
Enterprise Value | $654.37B | -$1.27M |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
NUWE trades at $1.43, up 0.7% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of -$17.52M in 2025, with a negative net income margin of -217.22%, though recent news highlights product development and revenue growth initiatives, including a 14% preliminary year-over-year revenue increase in Q2 2026.
Outlook is cautious due to persistent losses and high cash burn, but growth in pediatric installations and strategic expansions offer potential. Risks include financial sustainability and competitive pressures, while analyst coverage is limited with a split buy/hold consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
